mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS

Blood

Volumn 115, Issue 23, 2010, Pages 4758-4769

  Turnquist, Heth R ^a   Cardinal, Jon ^a   Macedo, Camila ^a   Rosborough, Brian R ^a   Sumpter, Tina L ^a   Geller, David A ^a   Metes, Diana ^a,b   Thomson, Angus W ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 23; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; CD86 PROTEIN, HUMAN; CD86 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; FOXP3 PROTEIN, MOUSE; INTERLEUKIN 12; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; INFLAMMATION; LYMPHOCYTE ACTIVATION; MALE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; DENDRITIC CELL; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE MUTANT;

ANIMALS; ANTIGENS, CD86; CELL DIFFERENTIATION; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INFLAMMATION; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYELOID CELLS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TH1 CELLS; TOLL-LIKE RECEPTORS;

EID: 77954748989     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-251488     Document Type: Article

References (49)

1. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
2. Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr Opin Cell Biol. 2009;21(2):209-218.
3. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22(2):159-168.
4. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9(5):324-337.
5. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105(12):4743-4748.
6. Monti P, Scirpoli M, Maffi P, et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T cells. Diabetes. 2008;57(9):2341-2347.
7. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood. 2002;100(3):1084-1087. (Pubitemid 34832646)
8. Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood. 2003;101(11):4457-4463.
9. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood. 2003;101(4):1439-1445. (Pubitemid 36182518)
10. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am J Transplant. 2005;5(2):228-236.
11. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178(11):7018-7031.
12. Turnquist HR, Sumpter TL, Tsung A, et al. IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol. 2008;181(1):62-72.
13. Reichardt W, Durr C, von Elverfeldt D, et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol. 2008;181(7):4770-4779.
14. Ohtani M, Nagai S, Kondo S, et al. mTOR and GSK3 differentially regulate LPS-induced IL-12 production in dendritic cells. Blood. 2008;112(3):635-643.
15. Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008;29(4):565-577.
16. Schmitz F, Heit A, Dreher S, et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol. 2008;38(11):2981-2992.
17. Wang Z, Larregina AT, Shufesky WJ, et al. Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T cell deletion and regulatory T cells. Am J Transplant. 2006;6(6):1297-1311. (Pubitemid 44030313)
18. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-490.
19. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5(6):446-458. (Pubitemid 40835033)
20. Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem. 2000;275(10):7416-7423.
21. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163-175.
22. Aksoy E, Vanden Berghe W, Detienne S, et al. Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kappa B activation and IFNbeta synthesis downstream of Toll-like receptor 3 and 4. Eur J Immunol. 2005;35(7):2200-2209.
23. Fukao T, Tanabe M, Terauchi Y, et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol. 2002;3(9):875-881.
24. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res. 2007;17(8):666-681.
25. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098- 1101.
26. Rodionova E, Conzelmann M, Maraskovsky E, et al. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood. 2007;109(4):1584-1592.
27. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005;6(8):777-784.
28. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 1998;17(5):1371-1384. (Pubitemid 28105516)
29. Caspi M, Zilberberg A, Eldar-Finkelman H, Rosin-Arbesfeld R. Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. Oncogene. 2008;27(25):3546-3555.
30. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009;284(12):8023-8032.
31. Miner KT, Croft M. Generation, persistence, and modulation of Th0 effector cells: role of autocrine IL-4 and IFN-gamma. J Immunol. 1998;160(11):5280-5287. (Pubitemid 28267814)
32. Zhao Z, Yu S, Fitzgerald DC, et al. IL-12R beta 2 promotes the development of CD4+CD25+ regulatory T cells. J Immunol. 2008;181(6):3870-3876.
33. Cao W, Manicassamy S, Tang H, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol. 2008;9(10):1157-1164.
34. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell. 2007;12(4):487-502.
35. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2(4):339-345.
36. de Jong EC, Smits HH, Kapsenberg ML. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol. 2005;26(3):289-307.
37. Zhu J, Paul WE. CD 4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557-1569.
38. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 2007;27(4):660-669.
39. MacDonald AS, Pearce EJ. Cutting edge: polarized Th cell response induction by transferred antigen-pulsed dendritic cells is dependent on IL-4 or IL-12 production by recipient cells. J Immunol. 2002;168(7):3127-3130.
40. Steinfelder S, Andersen JF, Cannons JL, et al. The major component in schistosome eggs responsible for conditioning dendritic cells for Th2 polarization is a T2 ribonuclease (omega-1). J Exp Med. 2009;206(8):1681-1690.
41. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19(1):225-252.
42. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7(8):610-621. (Pubitemid 47123548)
43. Wang Z, Hong J, Sun W, et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+CD25- T cells to CD4+ Tregs. J Clin Invest. 2006;116(9):2434-2441.
44. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood. 1995;86(6):2429-2438.
45. Gran B, Chu N, Zhang GX, et al. Early administration of IL-12 suppresses EAE through induction of interferon-gamma. J Neuroimmunol. 2004;156(1):123-131.
46. Singer SJ, Tiernan R, Sullivan EJ. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med. 2000;343(24):1815-1816.
47. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med. 2005;353(19):2088-2089.
48. Libetta C, Sepe V, Zucchi M, et al. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. Kidney Int. 2007;72(1):114-120.
49. Niemczyk M, Zegarska J, Pawlowska M,Wyzgal J, Ciszek M, Paczek L. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor. Transpl Immunol. 2009;20(3):139-142.